SCHEMBL4438790

SCHEMBL4438790

CCNNC(=O)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19639641 0.85 HDAC3 (0.33)
SCHEMBL1512247 0.77
Dimethylamine SCHEMBL10861087 0.72 LMNA (0.38)
SCHEMBL536155 0.72
Hydrochloric Acid SCHEMBL4440371 0.72 ALDH1A1 (0.39)
SCHEMBL3286238 0.72
SCHEMBL1880926 0.72 HDAC3 (0.31)
SCHEMBL749123 0.71
SCHEMBL261066 0.71
Methacrylic Acid SCHEMBL27551279 0.70 ALDH1A1 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4353236-A1 COMPOUND AND METHOD FOR TREATING CHEMOTHERAPY-RELATED GASTROINTESTINAL SIDE EFFECTS OnQuality Pharmaceuticals China Ltd. (CN) 2024-04-17 EP disclosed
EP-4353231-A1 COMPOUND AND METHOD FOR TREATING CHEMOTHERAPY-ASSOCIATED GASTROINTESTINAL SIDE EFFECTS OnQuality Pharmaceuticals China Ltd. (CN) 2024-04-17 EP disclosed
EP-2137188-B1 SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES Bayer Pharma AG (DE) 2012-06-06 EP disclosed
EP-2137188-A2 SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES Bayer Schering Pharma Aktiengesellschaft (DE) 2009-12-30 EP disclosed
WO-2008113469-A2 SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-09-25 WO disclosed
US-6303289-B1 Composition and methods for the treatment of cancer and viral infections ELENOR ROOSEVELT INSTITUTE 2001-10-16 US disclosed
US-20010029012-A1 Composition and methods for the treatment of cancer and viral infections ELEANOR ROOSEVELT INSTITUTE 2001-10-11 US disclosed
WO-2000056158-A1 COMPOSITION AND METHODS FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS ELEANOR ROOSEVELT INSTITUTE (US) 2000-09-28 WO disclosed